A
Adicet Bio, Inc. (ACET)
NCM – Real Time Price. Currency in USD
8.05
+0.50 (6.62%)
At close: Jun 12, 2026, 4:00 PM EDT
7.83
-0.22 (-2.73%)
After-hours: Jun 12, 2026, 6:18 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
8.05
+0.50 (6.62%)
At close: Jun 12, 2026, 4:00 PM EDT
7.83
-0.22 (-2.73%)
After-hours: Jun 12, 2026, 6:18 PM EDT
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Dr. Julie Maltzman M.D. | Chief Medical Officer |
| Mr. Brian Nicholas Harvey M.B.A. | Chief Financial Officer |
| Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director |
| Ms. Amy Locke | Chief Human Resource Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-20 | 10-K/A | acet-20251231.htm |
| 2026-05-13 | S-8 POS | 2026_s-8_pos.htm |
| 2026-05-13 | 10-Q | acet-20260331.htm |
| 2026-04-29 | DEFA14A | acet-20260429.htm |
| 2026-04-29 | ARS | acet-2025_annual_report.pdf |
| 2026-04-28 | 8-K | acet-20260427.htm |
| 2026-03-19 | CORRESP | filename1.htm |
| 2026-03-12 | S-3 | acet-20260312.htm |
| 2026-03-12 | 8-K | acet-20260312.htm |
| 2026-03-12 | 10-K | acet-20251231.htm |